The report highlights Genmab's commitment to sustainability and social responsibility through its core purpose of developing science-driven health innovations for patients. The company has made significant progress in 2023, including receiving approval for its first two co-owned medicines, epcoritamab and tisotumab vedotin-tftv, and expanding its pipeline of innovative antibody therapeutics to nine products. The report also details Genmab's progress in environmental sustainability, including completing its first full carbon footprint assessment and setting a climate target to reduce its greenhouse gas (GHG) emissions in line with the Paris Agreement. The company has also implemented several initiatives to promote diversity, equity, and inclusion (DE&I) within its workforce, including launching a new employee resource group, NextGen, and conducting additional implicit bias training for its recruiters. Finally, the report outlines Genmab's approach to value, access, and pricing, emphasizing its commitment to ensuring that its medicines reach the people who need them and that they are priced in a way that reflects the value of its innovation and its impact on patients.
